MENU
Go to the list of all blogs
Anna G's Avatar
published in Blogs
Mar 07, 2022

Cooper (COO, $423.86) beats earnings expectations

Cooper Companies reported its quarterly earnings results that surpassed analysts’ expectations.

 The medical device company’s earnings came in at $3.24 a share for the quarter, above the Zacks’ consensus estimate of $3.10.  The figure was $3.17 per share a year ago.

Cooper Companies revenue rose +15.7% from the year-ago quarter to  $787.20 million,  also exceeding analyst estimates of $739.30 million.

Looking ahead, Cooper expects its FY 2022 earnings in the range of $13.700-$14.200, and FY22 earnings of $13.70-$14.20 EPS.

Related Ticker: COO

Momentum Indicator for COO turns positive, indicating new upward trend

COO saw its Momentum Indicator move above the 0 level on November 12, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for COO just turned positive on November 12, 2025. Looking at past instances where COO's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

COO moved above its 50-day moving average on November 07, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where COO advanced for three days, in of 294 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where COO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

COO broke above its upper Bollinger Band on November 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for COO entered a downward trend on November 17, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. COO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.855) is normal, around the industry mean (9.206). P/E Ratio (38.206) is within average values for comparable stocks, (166.359). Projected Growth (PEG Ratio) (0.978) is also within normal values, averaging (2.581). COO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (3.865) is also within normal values, averaging (110.838).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 11.94B. The market cap for tickers in the group ranges from 246 to 203.56B. ISRG holds the highest valuation in this group at 203.56B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 3%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 6%. KRMD experienced the highest price growth at 33%, while MHUA experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 11%. For the same stocks of the Industry, the average monthly volume growth was 1% and the average quarterly volume growth was -23%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 61
Price Growth Rating: 60
SMR Rating: 78
Profit Risk Rating: 91
Seasonality Score: 26 (-100 ... +100)
View a ticker or compare two or three
COO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. COO showed earnings on August 27, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a maker of medical devices

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
6101 Bollinger Canyon Road
Phone
+1 925 460-3600
Employees
15000
Web
https://www.coopercos.com
Interact to see
Advertisement
Learn how to identify the four key market phases—Accumulation, Uptrend, Distribution, and Downtrend—and strategically trade each using Tickeron’s AI-powered Double Agent system. Discover how adaptive automation helps maximize gains and minimize risk across all market conditions.
#investment#artificial_intelligence
Learn how to identify the four key market phases—Accumulation, Uptrend, Distribution, and Downtrend—and strategically trade each using Tickeron’s AI-powered Double Agent system. Discover how adaptive automation helps maximize gains and minimize risk across all market conditions.
#artificial_intelligence#trading
Tickeron, a leader in AI-powered financial solutions, proudly announces the launch of its Double Agent Trading Bot, designed for trading Carpenter Technology Corporation (CRS) and Direxion Daily Semiconductor Bear 3x Shares (SOXS).
#artificial_intelligence
Apple Inc. (AAPL), a global leader in consumer electronics, continues to be a cornerstone of the technology sector, driving innovation and commanding significant market attention.
#artificial_intelligence
NVIDIA’s earnings on May 28 could jolt the tech sector. With market volatility rising, traders are turning to Tickeron’s AI Agent for real-time insights, predictive analytics, and dual-strategy trading tools to navigate potential price swings and seize market opportunities.
#artificial_intelligence
As the DOJ and FTC move to break up Google’s search dominance and impose AI investment oversight, the tech giant faces a pivotal legal battle that could reshape the digital and AI landscapes—creating major implications for investors, competitors, and consumers alike.
#artificial_intelligence
GameStop (GME) continues to captivate investors with its explosive volatility and strong retail sentiment. As AI tools highlight bullish signals and a possible breakout, traders weigh the risks of speculation against the potential rewards in May 2025.
#artificial_intelligence
Mastercard (MA) continues to impress investors with strong earnings, rising digital payments, and bullish AI-driven signals. Backed by robust financials and cutting-edge trading tools from Tickeron, MA stands out as a leader in the fintech space for 2025.
From Walmart's retail resilience to Exxon Mobil's energy strength, May 2025 highlights key market movers. Discover how Tickeron’s AI bots analyze WMT, IVW, COST, and XOM—uncovering trends, boosting trading strategies, and navigating market volatility with precision.
#trading#artificial_intelligence
A powerful recession signal is flashing red: the Leading/Lagging Ratio has plunged to levels not seen since 2008. As markets grow turbulent, smart investors are turning to Tickeron’s AI trading agents to spot opportunities and stay ahead of the downturn.
#trading#artificial_intelligence
AI trading bots are no longer just experimental—they’re outperforming traditional strategies. Discover how bots trading ITA, TSM, META, and others achieved over 40% annual returns and what this means for the future of investing.
FingerMotion (FNGR) is making waves in 2025 with a 52% stock surge, strategic AI expansion into Indonesia, and strong retail momentum. Learn how traders are using correlation analysis, inverse ETFs, and Tickeron’s AI tools to navigate FNGR’s dynamic moves.
#artificial_intelligence#trading
Ferrari (RACE) is accelerating in 2025 with a 25% YTD gain, strong earnings, and bullish momentum fueled by innovation and Lewis Hamilton’s F1 move. Discover how Tickeron’s AI tools help traders capitalize on this luxury stock’s high-performance potential.
Intel’s stock is down 64%, but a bold turnaround under new CEO Lip-Bu Tan and the upcoming 18A chip rollout could spark a rebound. This article explores Intel’s financials, strategic shifts, and how AI tools from Tickeron help traders navigate the volatility.
#artificial_intelligence
Dogecoin (DOGE) fell 12.78% in five days, rattled by whale activity, Musk headlines, and ETF rumors. Is a breakout coming—or more downside? Explore key trends, technical levels, and how Tickeron’s AI bots help traders navigate DOGE’s next move.
The week of June 2-6, 2025, saw financial markets demonstrate resilience amid U.S.-China trade tensions and key economic data releases.
Tesla, Inc. (TSLA), a global leader in electric vehicles (EVs) and artificial intelligence (AI)-driven technologies, has been a focal point for investors in 2025.
#artificial_intelligence#trading
As artificial intelligence continues to reshape the financial industry, AI-powered trading agents have emerged as influential tools in portfolio management and speculative trading.
#investment#artificial_intelligence
Amazon (NASDAQ: AMZN) remains a cornerstone of the technology and e-commerce sectors, consistently driving innovation and market influence.
#artificial_intelligence
ntroduction to Eli Lilly and Company (LLY) Eli Lilly and Company (LLY), a global pharmaceutical giant, has been a cornerstone of the healthcare sector since its founding in 1876. Headquartered in Indianapolis, Indiana, the company specializes in developing innovative treatments for diabetes, oncology, immunology, and neuroscience, with blockbuster drugs like Mounjaro and Zepbound driving significant…